Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc. has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Vancomycin Hydrochloride Capsules, USP, 125 mg and 250 mg, generic versions of ViroPharma Incorporated's Vancocin HCl capsules. Watson began shipping the products immediately.
Vancocin HCl capsules had total US sales of $332 million for the twelve months ending February 29, 2012, according to IMS Health. Vancocin HCl capsules are indicated for the treatment of C. difficile-associated diarrhoea and also for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
Watson Pharmaceuticals Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.